66176-93-0

Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity[1]. Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function[2].

Cimicifugoside, a triterpenoid extracted from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that synergistically enhances the cytotoxic effect of methotrexate. It has immunosuppressive activity that preferentially targets B cell function, requiring larger doses to inhibit T cell function.

[1] Yawata A, et al. Inhibition of nucleoside transport and synergistic potentiation of methotrexate cytotoxicity by cimicifugoside, a triterpenoid from Cimicifuga simplex. Eur J Pharm Sci. 2009 Nov 5;38(4):355-61. DOI:10.1248/bpb1978.3.643
[2] Hemmi H, et al. The immune response of splenic lymphocytes after cimicifugoside treatment in vitro and pretreatment in vivo. J Pharmacobiodyn. 1980 Dec;3(12):643-8. DOI:10.1248/bpb1978.3.643